EP Patent

EP2254561A2 — Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Assigned to Zynerba Pharmaceuticals Inc · Expires 2010-12-01 · 15y expired

What this patent protects

Described herein are compositions comprising opioids, opioid antagonists and prodrugs of the same, formulations comprising opioids, opioid antagonists and prodrugs of the same, and methods of using opioids, opioid antagonists and prodrugs of the same. One embodiment described her…

USPTO Abstract

Described herein are compositions comprising opioids, opioid antagonists and prodrugs of the same, formulations comprising opioids, opioid antagonists and prodrugs of the same, and methods of using opioids, opioid antagonists and prodrugs of the same. One embodiment described herein relates to the transdermal administration of a buprenorphine and encapsulated naltrexone in an abuse-resistant formulation for treating and preventing diseases and/or disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP2254561A2
Jurisdiction
EP
Classification
—
Expires
2010-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Zynerba Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.